GUANGDONG VTR BIO-TECH CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.41 CNY | +9.07% |
|
+19.96% | -26.59% |
Valuation
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 3,352 | 4,255 | 5,317 | 5,817 | 3,686 | 3,532 |
| Enterprise Value (EV) 1 | 4,303 | 5,110 | 5,783 | 6,388 | 2,276 | 2,427 |
| P/E ratio | 29.5 x | 32.9 x | 31.4 x | -48.9 x | 205 x | -337 x |
| Yield | 0.73% | 0.61% | 0.65% | 0.84% | 1.31% | - |
| Capitalization / Revenue | 1.9 x | 2.08 x | 2.78 x | 3.07 x | 3.14 x | 4.44 x |
| EV / Revenue | 2.43 x | 2.5 x | 3.02 x | 3.38 x | 1.94 x | 3.05 x |
| EV / EBITDA | 12.5 x | 13.8 x | 14.8 x | 34.1 x | 47.7 x | 27 x |
| EV / FCF | -12.2 x | -48 x | -359 x | 89.5 x | 2.92 x | -10.2 x |
| FCF Yield | -8.22% | -2.08% | -0.28% | 1.12% | 34.2% | -9.8% |
| Price to Book | 1.56 x | 1.77 x | 1.79 x | 2.08 x | 1.36 x | 1.39 x |
| Nbr of stocks (in thousands) | 406,755 | 429,326 | 490,058 | 490,065 | 483,773 | 479,194 |
| Reference price 2 | 8.240 | 9.910 | 10.85 | 11.87 | 7.620 | 7.370 |
| Announcement Date | 4/24/19 | 4/28/20 | 4/23/21 | 4/22/22 | 4/22/23 | 4/24/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales 1 | 1,768 | 2,048 | 1,915 | 1,892 | 1,174 | 796 |
| EBITDA 1 | 344.8 | 371.4 | 391.5 | 187.1 | 47.74 | 90.04 |
| EBIT 1 | 222.3 | 220.5 | 238.3 | 20.53 | -88.89 | -21.64 |
| Operating Margin | 12.57% | 10.77% | 12.44% | 1.09% | -7.57% | -2.72% |
| Earnings before Tax (EBT) 1 | 178.8 | 191.9 | 232 | -88.72 | 105.1 | 1.282 |
| Net income 1 | 113.5 | 127.5 | 161.7 | -118.9 | 18.23 | -10.75 |
| Net margin | 6.42% | 6.23% | 8.45% | -6.28% | 1.55% | -1.35% |
| EPS 2 | 0.2791 | 0.3009 | 0.3456 | -0.2426 | 0.0372 | -0.0219 |
| Free Cash Flow 1 | -353.8 | -106.4 | -16.1 | 71.41 | 779 | -237.9 |
| FCF margin | -20.01% | -5.19% | -0.84% | 3.77% | 66.35% | -29.88% |
| FCF Conversion (EBITDA) | - | - | - | 38.16% | 1,631.52% | - |
| FCF Conversion (Net income) | - | - | - | - | 4,272.52% | - |
| Dividend per Share 2 | 0.0600 | 0.0600 | 0.0700 | 0.1000 | 0.1000 | - |
| Announcement Date | 4/24/19 | 4/28/20 | 4/23/21 | 4/22/22 | 4/22/23 | 4/24/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | 951 | 856 | 466 | 571 | - | - |
| Net Cash position 1 | - | - | - | - | 1,410 | 1,105 |
| Leverage (Debt/EBITDA) | 2.758 x | 2.304 x | 1.189 x | 3.05 x | - | - |
| Free Cash Flow 1 | -354 | -106 | -16.1 | 71.4 | 779 | -238 |
| ROE (net income / shareholders' equity) | 6.7% | 6.64% | 6.75% | -2.71% | 1.28% | 0.04% |
| ROA (Net income/ Total Assets) | 3.21% | 2.96% | 3.24% | 0.28% | -1.45% | -0.43% |
| Assets 1 | 3,532 | 4,312 | 4,990 | -42,407 | -1,256 | 2,491 |
| Book Value Per Share 2 | 5.270 | 5.600 | 6.080 | 5.700 | 5.590 | 5.290 |
| Cash Flow per Share 2 | 2.310 | 0.4900 | 0.6200 | 0.5600 | 1.800 | 1.360 |
| Capex 1 | 311 | 398 | 283 | 163 | 198 | 394 |
| Capex / Sales | 17.59% | 19.43% | 14.78% | 8.61% | 16.85% | 49.52% |
| Announcement Date | 4/24/19 | 4/28/20 | 4/23/21 | 4/22/22 | 4/22/23 | 4/24/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
| 1st Jan change | Capi. | |
|---|---|---|
| -26.59% | 358M | |
| +11.33% | 11.43B | |
| -0.75% | 5.77B | |
| -5.10% | 4.14B | |
| -23.66% | 2.58B | |
| -4.34% | 1.75B | |
| -24.53% | 1.11B | |
| -23.66% | 882M | |
| -18.46% | 865M | |
| +25.81% | 855M |
- Stock Market
- Equities
- 300381 Stock
- Financials Guangdong VTR Bio-Tech Co., Ltd.
